Streetbeat News

Price Targets

TRIP

Ascendiant Capital has reaffirmed its Buy rating on TripAdvisor (NASDAQ:TRIP) and increased its price target from $27.00 to $30.00. TripAdvisor's shares have risen 0.73% to $21.48 recently. The new price target suggests a potential upside of 39.63%. TripAdvisor is a leading travel metasearch company with a diverse revenue stream from its hotel, experiences, and dining brands.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 5:00 pm

CTSO

HC Wainwright & Co. downgraded CytoSorbents (NASDAQ:CTSO) from a previous rating to Neutral and slashed the price target from $5.50 to $1.00. Following the downgrade, CTSO shares dropped by 5.07% to $1.03. The new price target suggests a further potential decline of 2.91%. CytoSorbents specializes in blood purification technology for critical care and cardiac surgery.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 5:00 pm

VTSI

Lake Street has reaffirmed its Buy rating on VirTra (NASDAQ:VTSI) and increased its price target from $9.00 to $13.00. VirTra's stock has risen 1.97% in the last 24 hours to $9.32 per share. The new price target suggests a potential upside of 39.48% from the current price. VirTra specializes in the development and sale of force training simulators for law enforcement, military, and commercial markets globally.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 5:00 pm

CCL

Macquarie has reaffirmed its Outperform rating on Carnival (NYSE:CCL) and increased its price target from $16.00 to $22.00. Carnival's stock is currently trading at $18.75, up 0.4% over the last 24 hours. The new price target suggests a potential upside of 17.36% from the current price. Carnival is the largest global cruise company and has recovered to its pre-COVID guest levels in 2023.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 5:00 pm

UCBI

Piper Sandler has maintained a Neutral rating on United Community Banks (NASDAQ:UCBI) and increased its price target from $27.00 to $28.00. Despite this, UCBI shares have declined by 0.74% to $29.71, which is above the new target. The bank operates through its subsidiary, Union Community Bank, with a focus on community banking services across Georgia, Tennessee, and the Carolinas.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 5:00 pm

BSX

Boston Scientific (NYSE:BSX) has been rated by 8 analysts over the last three months, with a mix of bullish and somewhat bullish opinions. The average 12-month price target is now $63.00, up from $60.62, with a high estimate of $66.00 and a low of $60.00. Analysts from firms like BTIG, Wells Fargo, Truist Securities, TD Cowen, Morgan Stanley, Canaccord Genuity, and Needham have maintained or adjusted their ratings and price targets. Boston Scientific specializes in less invasive medical devices and has a strong market presence with a high market cap and revenue growth, but faces challenges in ROE and ROA.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 5:00 pm

CGAU

Raymond James has maintained its Outperform rating for Centerra Gold (NYSE:CGAU) but reduced its price target from $12.00 to $11.00. Centerra Gold's shares are currently trading at $6.09, and the new price target suggests a potential upside of 80.62%. Centerra Gold is a gold mining company with operations in Asia, North America, and other regions.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 5:00 pm

CTSO

HC Wainwright & Co. analyst Sean Lee downgraded CytoSorbents (CTSO) from Buy to Neutral and reduced the price target from $5.5 to $1, indicating a more cautious outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 3:48 pm

GSK

PFE

SNY

TAK

Major pharmaceutical companies including Pfizer, Sanofi, and Takeda Pharmaceutical are planning to raise prices on over 500 drugs in the U.S. in early January, ahead of the Biden Administration's publication of discounted prices for ten high-cost drugs in September. This move is in response to inflation and increased manufacturing costs. Meanwhile, GSK is set to lower prices on at least 15 drugs in January, following price reductions on specific drugs for 2024. Drug price increases have been kept under 10% since 2019, reflecting a cautious approach by drugmakers.

Portfolio Pulse from Vandana Singh

December 29, 2023 | 3:31 pm

UCBI

Piper Sandler analyst Stephen Scouten has maintained a Neutral rating on United Community Banks (NASDAQ:UCBI) and increased the price target from $27 to $28.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 3:15 pm